Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Surrozen Inc SRZN

Healthcare Biotechnology
Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins... see more

Recent & Breaking News (NDAQ:SRZN)

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

GlobeNewswire April 3, 2024

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

GlobeNewswire April 1, 2024

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

GlobeNewswire April 1, 2024

Surrozen Provides Corporate Update on Clinical Programs

GlobeNewswire January 18, 2024

Surrozen Provides Third Quarter 2023 Financial Results

GlobeNewswire November 8, 2023

Surrozen Provides Second Quarter 2023 Financial Results

GlobeNewswire August 9, 2023

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

GlobeNewswire June 5, 2023

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

GlobeNewswire May 10, 2023

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

GlobeNewswire April 5, 2023

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

GlobeNewswire March 22, 2023

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

GlobeNewswire March 20, 2023

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2022

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

GlobeNewswire October 10, 2022

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

GlobeNewswire October 6, 2022

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

GlobeNewswire September 26, 2022

Surrozen Reports Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

GlobeNewswire June 13, 2022

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

GlobeNewswire May 24, 2022

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

GlobeNewswire May 18, 2022